tor reduction and elimination of infected reservoir) for American leishmaniasis.
The solid protective immunity observed in humans following convalescence to CL formed the basis for practice of active immunization, beginning with deliberate inoculation of virulent organisms ("leishmanization") in centuries past and continuing with vaccination using a crude antigen preparation obtained from inactivated ("killed") promastigotes of one or various species of Leishmania, formulated either with or without BCG (bacillus of Calmette and Guerin) as an adjuvant (Grimaldi 1995) . While accumulated experience with mass vaccination both in the ex-USSR and in Israel has clearly shown that a virulent strain of Leishmania must be used for vaccination to succeed (Gunders 1987) , several Phase III trials testing the potential efficacy of various crude vaccine approaches have given conflicting results. Overall, the results vary from 0-75% efficacy against CL and little (< 6%) or no protection against VL (Grimaldi 1995 , Coler & Reed 2005 . Although host genetics can have dramatic effects on T-cell responses to existing vaccines (Lambert et al. 2005) , several technical problems (including inadequate information about the quality, stability and potency of the antigens) may provide explanation for some of the variation in efficacy observed in those human vaccine studies. Nevertheless, most experts believe that a preventive vaccine will be essential if this disease is ever to be controlled worldwide (Coler & Reed 2005 , Tabbara 2006 , Kedzierski et al. 2006 , Palatnik-de-Souza 2008 , Silvestre et al. 2008 .
The current effort to develop improved vaccines for leishmaniasis has led to the need for appropriate animal models in which to test candidate vaccines (Hein & Griebel 2003) . There are reminders that the results from rodent models do not automatically translate to humans (MacGregor et al. 1998) . The use of non-human primates (NHP) as animal models for the study of human diseases (including immunological studies and drug and vaccinedevelopment studies against infectious diseases) has become increasingly important , Delgado et al. 2005 , Giavedoni 2005 , Gibbs et al. 2007 , Nikolich-Žugich 2007 , Souza-Lemos et al. 2008 . For instance, the SIV-macaque model is widely used for testing vaccine and therapeutic strategies prior to conducting human clinical trials (Nathansson et al. 1999 , Hu 2005 . This review aims to provide insight into the current knowledge on vaccine studies against leishmaniasis, with emphasis on studies involving vaccination and experimental infection in monkeys.
Vaccine studies against leishmaniasis
A major international research effort over the past 20 years has resulted in the identification of various Leishmania antigen candidates for second and thirdgeneration vaccines (Coler & Reed 2005 , Palatnik-deSouza 2008 . Information about a multitude of immunization approaches representing all of the major vaccine design strategies, including vaccines using live genetically attenuated parasites, subunit proteins/peptides in adjuvants, naked DNA and infectious vectored vaccines expressing genes coding for specific leishmanial antigens and combinations thereof has been given in recent review articles (Coler & Reed 2005 , Tabbara 2006 , Kedzierski et al. 2006 , Palatnik-de-Souza 2008 , Silvestre et al. 2008 ). Many of these vaccines have been tested for immunogenicity and protective efficacy in a variety of experimental models (such as inbred laboratory rodents, dogs and NHP). Depending on the particular vaccine approach and animal model used, varying degrees of protective immunity have been achieved, as determined by the level of parasite burden in infected sites and/or lesion size following infectious challenge.
Vaccination strategies are based on the immunology of Leishmania infection (Vanloubbeeck & Jones 2004 , Von Stebut 2007 . On the basis of compelling evidence that both CD4 + (including multifunctional Th1 cells and central memory CD4 + T-cells) and CD8 + T-cells are key players in the immune response to leishmaniasis (Reed & Scott 2000 , Zaph et al. 2004 , Darrah et al. 2007 ), the scientific community has focused considerable efforts on the development of prophylactic vaccines that elicit T-cell responses (Rhee et al. 2002 , Tapia et al. 2003 , Sharma et al. 2006 , Dondji et al. 2008 ) with the premise that such interventions will confer protective effects in these conditions. In this regard, sustained protective immunity against both murine CL and VL has been achieved by DNA vaccines encoding antigen candidates (Gurunathan et al. 2000 , Mendez et al. 2001 , CamposNeto et al. 2002 , Zanin et al. 2007 , Dondji et al. 2008 or leishmanial recombinant protein(s) formulated with improved vaccine adjuvants (Pashine et al. 2005) , including cytosine phosphate guanosine oligodeoxynucleotides, CpG ODN (Rhee et al. 2002 , Iborra et al. 2005 and cationic distearoyl phosphatidylcholine (DSPC) liposomes (Bhowmick et al. 2007) . Of note, long-term immunity elicited by those vaccines corresponded to, in addition to the presence of leishmania-specific Th1,
CD8
+ T-cells responses (Gurunathan et al. 2000 , Rhee et al. 2002 , Sharma et al. 2006 . Additionally, heterologous prime-boost vaccination regimes, such as combining DNA priming with a live vectored boost (Gonzalo et al. 2002 , Ramiro et al. 2003 , or two different live vectors to prime and boost a response (Dondji et al. 2005 , Ramos et al. 2008 have been explored as a means of raising protective T-cell responses (Hu 2005) .
Due to the genetic variability of human T-cell responses (across HLA haplotypes), T-cell vaccines can elicit variable protective immunity (Robinson & Amara 2005) . A second limitation of T-cell vaccines is the potential for T-cells to become exhausted by high levels of persisting antigens (Kostense et al. 2002) . Another challenge is the ability of leishmanial parasites to modulate their antigens to evade immune responses (Vanloubbeeck & Jones 2004) . Therefore, a successful DNA or subunit protein-based vaccine will likely require a cocktail of proven immunogens. Accordingly, there is increasing emphasis on strategies for combining protective antigen candidates in the same regimen , Iborra et al. 2004 , Zadeh-Vakili et al. 2004 , Moreno et al. 2007 , Rodriguez-Cortés et al. 2007 , Zanin et al. 2007 ). It should be noted that a triple fusion protein vaccine (termed Leish-111f-MPL ® -SE), consisting of the T-cell adjuvant antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1 and Leishmania elongation initiation factor formulated in monophosphoryl lipid A plus squalene, which confers protection in the mouse model against L. major, Leishmania amazonensis (Coler & Reed 2005) and Leishmania infantum infections (Coler et al. 2007 ) is now within reach. Whether prophylactic immunization using this vaccine can achieve similar levels of immunity against all parasite species that cause disease in genetically diverse human subjects (who also may differ significantly in their nutritional status and previous immunological experience) has yet to be determined.
Additionally, the potential efficacy of the Leish-111f/ GM-CSF adjuvant vaccine in a post-exposure paradigm is currently being tested in cases of drug-refractory disease with encouraging results (Badaró et al. 2006) . On the other hand, the potential for immunomodulatory factors of sandfly saliva to serve as vaccine targets to prevent pathogen transmission (Titus et al. 2006 ) has received increased attention by investigators. In this regard, two candidates are the Lutzomyia longipalpis salivary gland protein maxadilan (Brodie et al. 2007 ) and the recombinant protein SP15; a vaccine composed of the latter antigen confers protection in the mouse model against L. major challenge infection (Valenzuela et al. 2001 ). Table I summarizes the published studies on natural leishmanial infections in NHP. At least four species of Neotropical monkeys are susceptible to natural infection with human pathogenic Leishmania (Viannia) species (Herrer et al. 1973 , Lainson et al. 1988 . In contrast, only one species of old world monkeys was found to be naturally infected with L. major ). Monkeys have varying degrees of susceptibility to leishmanial parasites and the specific disease course depends on the challenge parasite (Amaral et al. 1996 , Teva et al. 2003 , host species or individual (Dennis et al. 1986 , Porrozzi et al. 2006 ) challenge dose and route of exposure (Lujan et al. 1986a , Amaral et al. 1996 . Moreover, sand fly saliva immunomodulators are known to exacerbate leishmanial infection in rodents (Lima & Titus 1996) . Accordingly, when rhesus macaques are infected with L. major transmitted by Phlebotomus papatasi (Probst et al. 2001) , they developed skin lesions that lasted longer (12-28 weeks post-infection) than typical infections (11 weeks) induced by needle inoculation with larger numbers (1 x 10 7 ) of L. major culture metacyclics (Amaral et al. 2001) . Table II summarizes the essential features of the published studies on experimental infection of NHP by various Leishmania species. Different NHP species have become useful in studying the biology of infection and in dissecting the host response to these parasites. Those reported as being highly susceptible to Leishmania donovani complex parasites include the Neotropical simians Aotus trivirgatus , Broderson et al. 1986 , Saimiri sciureus , Dennis et al. 1985 and Callithrix jacchus jacchus (Marsden et al. 1981) . All of these species have since been used as NHP models of VL for anti-leishmanial chemotherapy studies (Dietze et al. 1985 , Madindou et al. 1985 , Berman et al. 1986 ). Conversely, East African primates such as Sykes monkeys (Cercopithecus mitis) and baboons (Papio cynocephalus) all supported low-grade L. donovani infections for periods ranging between 4-8 months and subsequently showed evidence of self-cure (Githure et al. 1986 ). Furthermore, disease mimicking human VL was established in langur monkeys (Presbytis entellus) (Dube et al. 1999) , vervet monkeys (Cercopithecus aethiops) (Binhazim et al. 1993 and macaques (Macaca mulatta) (Porrozzi et al. 2006) . The L. donovani-langur monkey model has also been explored to assess different vaccine formulations against VL (Dube et al. 1998 , Misra et al. 2001 .
Natural and experimental leishmanial infections in NHP
Consistent with documented cases of human CL caused by L. major, experimental infection in macaques induced by the same parasite species causes a self-limiting CL of moderate severity ( Fig. 1) , which resolves within three months ( Fig. 2 ) and provides the most ethically acceptable model for vaccine testing (Amaral et al. 2001 ). When infected with L. amazonensis, macaques developed greater lesion size with longer duration (Amaral et al. 1996) . In both experiments, active skin lesions contained amastigotes with a mononuclear infiltrate of macrophages, plasma cells and lymphocytes and formation of tuberculoidtype granulomas. In L. amazonensis-infected macaques it was demonstrated that CD4 + /CD8 + T-cell ratios favour CD8 + cells in both active and healing skin lesions (Amaral et al. 2000) . A more marked variation in the clinical course of infection was found when groups of macaques were inoculated with different Leishmania braziliensis strains (Teva et al. 2003 , Souza-Lemos et al. 2008 . The inocula produced lesions of variable severity, ranging from localized self-healing CL to nonhealing disease (Figs 3A, C). Pathological findings included a typical cell-mediated immunity-induced granulomatous reaction (Fig. 3D) , which consisted of all cell types found within human granulomas, including the presence of both IFN-γ-or TNF-α-producing CD4 + and CD8 + T-cells, as well as IL-10-producing CD4 + CD25 + T-cells (Souza-Lemos et al. 2008) . While several groups have described that ML (mucosa lesions) has not been observed in Neotropical monkey models of CL (Lainson & Shaw 1977 , Lujan et al. 1986a , Cuba Cuba et al. 1990 , in our own studies (Teva et al. 2003, G Grimaldi Jr, unpublished data) two of 30 (6.7%) L. braziliensis-infected macaques developed nasal ML (Fig. 3C ). In the original model description (Marques da Cunha 1944), ML was observed in two of seven (28.5%) monkeys infected with L. braziliensis. Of note, therapeutic responses of L. braziliensis-infected macaques to the reference drug N-methylglucamine antimoniate (Glucantime ® ) were consistent with those reported in human disease (Teva et al. 2005) .
Contrary to the traditional belief that human self-resolution of CL confers life-long immunity against further infection by the same parasite (Gunders 1987) , KillickKendrick et al. (1985) and Saraiva et al. (1990) provided evidence that immunity conferred by prior self-resolving leishmanial infection may not always be complete in humans. Likewise, in L. amazonensis (Amaral et al. 1996) or L. major-infected out-bred macaques (Amaral et al. 2001 ) both the level of resistance and the acquired immune response to subsequent homologous challenge(s) are variable. The mechanism causing partial protection in primates is not yet clear, but may be related to differ- ential performance of memory T cells (Zaph et al. 2004 ).
In addition, IL-10-producing CD4 + CD25 + T cells are known to control acquired immunity in mice (Belkaid et al. 2002) and macaques (Souza-Lemos et al. 2008 ) with leishmanial infections.
The findings from cross-immunity experiments between different species or strains of Leishmania in monkeys (Table III) may give important clues to vaccine reseach. The relative variability in protection after self-cure or drug-cured experimental leishmaniasis to challenge by heterologous parasites appears to reflect both the nature (i.e., etiologic agent) and the course of primary infection or disease tempo (i.e., the progression and resolution of leishmanial lesions). Another factor that can influence acquired immunity is the time between recovery from primary infection and re-challenge. For example, a self-healing CL following infection with L. major induces significant protection for L. amazonensis and Leishmania guyanensis and was dependent on time of re-challenge by L. amazonensis after animals had recovered from primary lesions, but lacked protection against L. braziliensis. Conversely, macaques immune to either L. braziliensis or Leishmania chagasi (syn. L. infantum) were found to be fully protected to challenge with L. braziliensis or L. amazonensis (Porrozzi et al. 2004 ).
All infected animals responded with increased production of immunoglobulins capable of binding to cross-reacting parasite antigens (Lujan et al. 1987 , Porrozzi et al. 2004 . Although an antigen-specific Th1-like response appears critical for mediating protection in a variety of primate models of CL (Olobo et al. 1992 , Olobo & Reid 1993 , Amaral et al. 2001 , Teva et al. 2003 and VL (Porrozzi et al. 2006) , the current parameters of cell-mediated immunity [i.e., by measuring delayed-type hypersensitivity reaction (DHT) to the leishmanin skin test (LST) in vitro lymphocyte proliferation and IFN-γ production] do not always correlate with clinical recovery and resistance to infectious re-challenge (Amaral et al. 2001 , Porrozzi et al. 2004 , 2006 . Certainly, further studying the immune response in primates may clarify what is required to develop and maintain protective immunity to re-challenge(s). (Amaral et al. 1996) was injected intradermally into the orbit of the right eye of each monkey. All of the challenge-infected monkeys developed a typical ulcerated skin lesion at the site of inoculation (Fig. 1) . Skin lesions were measured as previously described (Teva et al. 2003 ).
Use of primate models to assess leishmaniasis vaccines
Divergent evolution (~ 210 million year divergence between rodents and humans) limits the relevance of murine models in guiding the design of human vaccine trials (Nikolich-Žugich 2007). In this regard, old world simian species which diverged from humans approximately 25 million years ago (Gibbs et al. 2007 ) are emerging as invaluable in vivo models of pathogenesis and immunity to infectious diseases requiring cellular immunity, but are also a key tool for conducting comparative studies of vaccine approaches (Nathansson et al. 1999 , Jonhston 2000 . Because of the homology between the M. mulatta and human immune systems (Kennedy et al. 1997b , Shearer et al. 1999 , Pahar et al. 2003 , Giavedoni 2005 ), the NHP model is frequently used to determine which vaccine candidates are most worthy of accelerated development (Johnston 2000 , Nikolich-Žugich 2007 .
A variety of NHP models for both CL and VL have been used to assess the safety (to verify whether vaccination itself causes adverse effects), immunogenicity (including evaluation of potential correlates of immune protection) and protective efficacy (to determine whether vaccination protects the animal host against infective challenge) of vaccine formulations (Table IV) . To date, the only way to determine acquired resistance afforded by a candidate vaccine is to challenge the vaccinated animals with virulent leishmanial parasites. However, because of (i) the limited number of monkeys per experimental group and (ii) the fact that stationaryphase promastigotes can have varying numbers of the infectious form of metacyclic promastigotes within each preparation, researchers use a high inoculum dose to achieve uniform infection for challenge, which may account for the relative variability in the levels of vaccineinduced protection. On the other hand, the use of a short interval between the last boost and the infectious challenge (as short as 3-5 weeks in some studies), makes it difficult to interpret the results in terms of the ability of the vaccine to induce a sustained memory T-cell response (Pitcher et al. 2002) . In addition, in most studies of this nature, it is difficult to accurately assess partial host immunity during infection since lesion size, a highly variable parameter (due to the out-bred nature of monkeys used for such studies) is commonly used as a correlate of protection.
The results from primate vaccine studies are summarized in Table IV . Protective efficacy with crude vaccine approaches against CL in macaques was achieved only when the inactivated parasites were combined with alum plus recombinant human IL-12 (Kenney et al. 1999) or CpG ODN (Verthelyi et al. 2002) as adjuvants. In addition, successful vaccination against L. donovani visceral infection in langur monkeys was obtained using alumprecipitated autoclaved L. major with BCG (Misra et al. 2001) . In our previous studies (Amaral et al. 2002) we have compared the potential efficacy of two L. major vaccines, one genetically attenuated (DHFR-TS deficient organisms), the other inactivated organisms (autoclaved promastigotes with BCG), in protecting macaques against homologous challenge. While a positive antigen-specific recall proliferative response was observed in those vaccinated (79% in attenuated parasite-vaccinated monkeys, versus 75% in ALM-plus-BCG-vaccinated animals), none of these animals exhibited either augmented in vitro INF-γ production or a positive DTH response to the leishmanin skin test prior to challenge. Following challenge, significant differences in blastogenic responses were found between attenuated-vaccinated monkeys and naïve controls. Protective immunity did not follow vaccination, in that monkeys exhibited skin lesions at the site of challenge in all experimental groups. In contrast, vaccination using a mix of the recombinant antigens LmSTI1 and TSA (Webb et al. 1996 (Webb et al. , 1998 formulated with rhIL-12 and alum as adjuvants induced excellent protection in the high dose L. major-macaque model . Likewise, vervet monkeys, when immunized with recombinant histone H1 antigen using Montanide as an adjuvant, mounted good protection against challenge with L. major (Masina et al. 2003) .
Ample evidence supports the notion that different prime-boost vaccination regimens can elicit greater immune responses than single immunization modalities. The use of heterologous prime-boost approaches was originally explored as a means to overcome vector-specific immunity elicited against the priming immunogen and to augment antigen-specific responses by subunit protein boost (Hu et al. 1991) . This approach was found to enhance antigen-specific antibody responses in mice, macaques and humans primed with a recombinant vaccinia virus and boosted with recombinant HIV-1 envelope protein (Hu 2005) . Conversely, immunization with DNA priming and recombinant virus boosting elicited strong T-cell responses (Schneider et al.1999 , Barouch & Letvin 2000 . The effect regarding the order of DNA versus recombinant vector for priming or boosting can have in eliciting protective immunity has been debated (Hanke et al. 1998 , McClure et al. 2000 . Over the past three years, several primate studies have been performed in our laboratory to establish vaccination procedures, improve vaccine immunogenicity and minimize vector-specific immunity. Indeed, it is now clear that detectable Leishmania-specific T-cell responses can be induced safely in primates by vaccination, but, depending on the particular regimen used, varying degrees of acquired immunity have been achieved (ranging from non-existent to full protection after the infectious challenge). Further experiments are in progress in the Leishmania-macaque model to comparatively examine the potential efficacy of various vaccine approaches afforded by vaccine candidates. a: number of animals used in each experiment; b: monkeys were rechallenge-infected after they had recovered from previous (primary, secondary and/or tertiary) infection(s). In some experiments, animals were injected with the same parasite strain/dose, but at different time points as indicated (at 28 † and 44 ‡ weeks post-infection); c: as indicated by the level of clinical resistance to each rechallenge: complete (no lesion), partial (lesion size was smaller and healed faster than in the primary infection) or lack (failure) of protection. In this case, individuals that had recovered from previous infection(s) remained susceptible to the last rechallenge; d: host infected twice with the same parasite; e: animals were rechallangeinfected nine months after primary lesion resolution. prom: promastigotes; rGP63: a recombinant L. major glycoprotein (the major leishmanial surface glycoprotein); rGST-H1: a recombinant glutathione-S-transferase fused to L. major histone H1 nuclear antigen (that has no homology to human H1 protein); rhIL-12: recombinant human interleukine-12 (act as adjuvant); rLmSTI1: a recombinant L. major homolog of the eukaryotic stress-inducible protein-1 (Webb et al. 1997) ; rTSA: a recombinant L. major homolog of the eukaryotic thiol-specific antioxidant protein (Webb et al. 1998) ; sb: subcutaneously; sc: subcutaneous; SUPV: subunit protein-based vaccine.
Determining correlates of immune protection to Leishmania
While the functional heterogeneity (across HLA haplotypes) of T-cell cytokine responses to existing vaccines is undoubtedly of importance (Robinson & Amara 2005) , they have not been extensively analyzed. In fact, T-cell vaccines for microbial infections have been developed without a clear understanding of their mechanism(s) of protection (Lambert et al. 2005) . With regard to leishmaniasis, most vaccine studies measure the frequency of IFN-γ-producing Th1 cells as the primary immune correlate of protection (Coller & Reed 2005) , but in vitro IFN-γ production as a single immune parameter may not be sufficient to predict protection (Elias et al. 2005 . Recent data have shed important insight on the potential correlates of protection, showing that the magnitude, potency and durability of a multifunctional CD4 + Th1-cell cytokine response can be a crucial determinant in whether a vaccine is protective (Darrah et al. 2007) . Conversely, it is likely that IL-10-producing CD4 + CD25 + T regulatory cells are functional in determining vaccine failure (Stober et al. 2005) . In another study (Stäger et al. 2000) , vaccine-induced protection, using the recombinant hydrophilic acylated surface protein B1 (HASPB1) of L. donovani, correlates with the presence of rHASPB1-specific, IFN-γ-producing CD8 + T cells. Neither study in the L. amazonensis (Kenney et al. 1999) or L. major-macaque model , Amaral et al. 2002 , nor those in the L. major-vervet monkey model (Gicheru et al. 2001) , have resulted in a clear definition of what T-cell responses will be required for vaccine-induced protective immunity. Without such knowledge, vaccine design strategies will remain largely empirical, and further failures are likely to occur. This is due, in part, to the high degree of variability in the antigen-specific recall blastogenic and IFN-γ responses detected among primates , Pahar et al. 2003 ). This appears to result from the outbred genetics of macaques used for such studies, which indeed makes them the most appropriate model when predicting the diversity of responses that could be expected in the human population. Increasing the number of monkeys per experimental group can help address this condition. Unfortunately, by definition this is not feasible. On the other hand, using macaques with defined genotypes with respect to immune response genes (MHC class I and II) would minimize individual variability, but unfortunately this approach introduces bias into the results (Johnston 2000 , Hu 2005 .
Finally, the application of ELIspot and cytokine flow cytometry assays has provided new insights into the attributes of both CD4 + and CD8 + T cells that mediate protection in macaques (Mäkitalo et al. 2002 , Keeney et al. 2003 . This technology should help to identify correlates of protection in future primate vaccine studies.
Concluding remarks
Clinical development of the available subunit protein or DNA-based vaccines against leishmaniasis may not be fully protective across all HLA haplotypes and Leishma-nia species. This is due, in part, to the inherent difficulties that hinder full characterization of the determinants of successful T-cell immunity in humans (Robinson & Amara 2005 , Appay et al. 2008 . Nevertheless, most experts believe that a successful Leishmania vaccine will likely require (i) selection of a cocktail of protective immunogens; (ii) identification of efficient prime-boost strategies in order to provide broad, cross-reactive and long-lasting protection; and (iii) selection or identification of an adjuvant formulations or delivery systems that can be used in human clinical trials. Nonetheless, given these intrinsic vaccine development requirements, regulatory authorities are willing to regulate safety data on infectious vectored vaccines generated from primates.
However, primate testing should be reserved for the final stages of evaluation of vaccine candidates that have already shown consistent induction of significant protective immunity in conventional mouse models. Considerations for employing the primate M. mulatta to evaluate vaccine safety and protective efficacy should also include costs and availability (Kennedy et al. 1997a) . Available data indicates that vaccine trials in macaques will not be hindered due to divergence of MHC class I and class II molecules (Watkins et al. 1988 , Klein et al. 1993 , Doxiadis et al. 2001 . Moreover, rhesus macaques have been successfully infected with a variety of human pathogenic Leishmania species either by syringe or sandfly challenge and develop a human-like disease (including the non-curing L. braziliensis granulomata ML). Most of the published information on the course of primary or secondary infection, clinicopathological changes, immune responses and vaccination data was gained using outbred macaques. Although the predictive value for any animal model in vaccine development ultimately depends on validating data from human trials, further development of the Leishmania-macaque model should prove useful in guiding the design of human vaccine trials.
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